ICAM1 and melanoma: The immunomodulatory activity of different DHAs on the constitutive expression levels of HLA class I antigens and the co-stimulatory molecule, ICAM-1, was evaluated in 14 melanoma cell lines and 10 hematological cancer cell lines treated with 1 μM guadecitabine, DAC or AZA, by flow cytometry.